Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma

PURPOSE: There is increasing recognition that progress in immuno-oncology could be accelerated by evaluating immune-based therapies in dogs with spontaneous cancers. Osteosarcoma (OS) is one tumor for which limited clinical benefit has been observed with the use of immune checkpoint inhibitors. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Regan, Daniel P., Chow, Lyndah, Das, Sunetra, Haines, Laurel, Palmer, Eric, Kurihara, Jade N., Coy, Jonathan W., Mathias, Alissa, Thamm, Douglas H., Gustafson, Daniel L., Dow, Steven W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866227/
https://www.ncbi.nlm.nih.gov/pubmed/34580111
http://dx.doi.org/10.1158/1078-0432.CCR-21-2105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866227/
https://www.ncbi.nlm.nih.gov/pubmed/34580111
http://dx.doi.org/10.1158/1078-0432.CCR-21-2105

Ejemplares similares